长春高新：前三季度净利润同比减少58.23%，长期股权投资同比增长149.56%

Core Viewpoint - Changchun High-tech reported a decline in both revenue and net profit for the first three quarters of the year, indicating significant challenges in its financial performance [1] Financial Performance - For the first three quarters, the company achieved operating revenue of 9.807 billion, a year-on-year decrease of 5.60% [1] - The net profit attributable to shareholders was 1.165 billion, down 58.23% year-on-year [1] - In Q3 alone, operating revenue was 3.204 billion, reflecting a 14.55% year-on-year decline [1] - The net profit for Q3 was 182 million, a substantial decrease of 82.98% year-on-year [1] Subsidiary Performance - The net profit of subsidiary Jinsai Pharmaceutical decreased by 49.96% year-on-year [1] - The net profit of subsidiary Baike Biological plummeted by 164.76% year-on-year [1] Investment Activities - The company's long-term equity investments increased by 435 million compared to the beginning of the year, marking a growth of 149.56% [1] - This increase was primarily due to Baike Biological's second-phase capital increase in Chuanxin Biological, with an additional investment of 200 million, raising the company's ownership stake to 33.3241% [1]